Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR13780253

— · cohortMD1

469e4f7f-4a56-55d0-832f-e1b33fac9c99

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortMD1
subtype
cohortMD1

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.710
  • MYC_TARGETS_V1+0.650
  • OXIDATIVE_PHOSPHORYLATION+0.550
  • MTORC1_SIGNALING+0.480
  • PANCREAS_BETA_CELLS+0.440
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.420
  • IL6_JAK_STAT3_SIGNALING+0.410
  • TNFA_SIGNALING_VIA_NFKB+0.410
  • UNFOLDED_PROTEIN_RESPONSE+0.400
  • ALLOGRAFT_REJECTION+0.380

Top 10 suppressed

  • MITOTIC_SPINDLE-0.330
  • UV_RESPONSE_DN-0.200
  • NOTCH_SIGNALING-0.190
  • HEDGEHOG_SIGNALING-0.140
  • WNT_BETA_CATENIN_SIGNALING-0.130
  • MYOGENESIS-0.120
  • APICAL_JUNCTION-0.090
  • KRAS_SIGNALING_DN-0.080
  • BILE_ACID_METABOLISM-0.060
  • HEME_METABOLISM-0.030

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR6013500
lung-landscapes@6
—cohortA10.896
2TCGA-18-3415-01A-01R-0980-07
lung-landscapes@6
—cohortSQ20.891
3SRR6013499
lung-landscapes@6
—cohortA10.888
4SRR11296801
colon-landscapes@1
——0.883
527875588-7C41-49BB-A4C0-A66D72A12499
brain-umap@2
——0.883
6MDT-AP-2506
medullo-epn-umap@date-based
MedMedulloblastoma0.877
7MDT-AP-0370
medullo-epn-umap@date-based
MedMedulloblastoma0.873
8TCGA-G2-A2EO-01A-11R-A180-07
bladder-landscape@3
——0.865
9s0094253
melanoma-umap@29
——0.859
10TCGA-05-4395-01A-01R-1206-07
lung-landscapes@6
—cohortA40.856

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 39 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.710Idelalisib— uncovered
MYC_TARGETS_V10.650Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.550Remibrutinib— uncovered
MTORC1_SIGNALING0.480Inavolisib— uncovered
PANCREAS_BETA_CELLS0.440Cobimetinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.420Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.410Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.410Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.400Idelalisib— uncovered
ALLOGRAFT_REJECTION0.380Idelalisib— uncovered
UV_RESPONSE_UP0.380Idelalisib— uncovered
E2F_TARGETS0.360Inavolisib— uncovered
COMPLEMENT0.350Inavolisib— uncovered
FATTY_ACID_METABOLISM0.350Inavolisib— uncovered
GLYCOLYSIS0.350Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.340Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.300Inavolisib— uncovered
HYPOXIA0.290Idelalisib— uncovered
ANDROGEN_RESPONSE0.280Inavolisib— uncovered
KRAS_SIGNALING_UP0.280Inavolisib— uncovered